156 related articles for article (PubMed ID: 24331695)
1. [Anti-proliferation effect of sorafenib in combination with 5-FU for hepatocellular carcinoma in vitro: antagonistic performance and mechanism].
Deng LF; Wang YH; Jia QA; Ren ZG; Shen HJ; Sun XJ; Li JH
Zhonghua Gan Zang Bing Za Zhi; 2013 Nov; 21(11):845-9. PubMed ID: 24331695
[TBL] [Abstract][Full Text] [Related]
2. Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma.
Deng L; Ren Z; Jia Q; Wu W; Shen H; Wang Y
BMC Cancer; 2013 Jul; 13():363. PubMed ID: 23895220
[TBL] [Abstract][Full Text] [Related]
3. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
[TBL] [Abstract][Full Text] [Related]
4. Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study.
Zhang Z; Zhou X; Shen H; Wang D; Wang Y
BMC Med; 2009 Aug; 7():41. PubMed ID: 19698189
[TBL] [Abstract][Full Text] [Related]
5. [Suppression of the growth of subcutaneous transplanted human liver cancer and lung metastasis in nude mice treated by sorafenib combined with fluorouracil].
Shen HJ; Wang YH; Xu J
Zhonghua Zhong Liu Za Zhi; 2013 Feb; 35(2):98-102. PubMed ID: 23714662
[TBL] [Abstract][Full Text] [Related]
6. Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT.
Mao J; Yang H; Cui T; Pan P; Kabir N; Chen D; Ma J; Chen X; Chen Y; Yang Y
Eur J Pharmacol; 2018 Aug; 832():39-49. PubMed ID: 29782854
[TBL] [Abstract][Full Text] [Related]
7. [Coadministration of sorafenib and cisplatin inhibits proliferation of hepatocellular carcinoma HepG2 cells in vitro].
Chen FS; Cui YZ; Luo RC; Wu J; Zhang H
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(9):1684-7. PubMed ID: 18819900
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1.
Zhai JM; Yin XY; Lai YR; Hou X; Cai JP; Hao XY; Liang LJ; Zhang LJ
Cancer Chemother Pharmacol; 2013 May; 71(5):1255-64. PubMed ID: 23435877
[TBL] [Abstract][Full Text] [Related]
9. YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma.
Kong J; Kong F; Gao J; Zhang Q; Dong S; Gu F; Ke S; Pan B; Shen Q; Sun H; Zheng L; Sun W
Mol Cancer; 2014 Jan; 13():7. PubMed ID: 24418169
[TBL] [Abstract][Full Text] [Related]
10. Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft--no benefit of combination therapy.
Wehler TC; Hamdi S; Maderer A; Graf C; Gockel I; Schmidtmann I; Hainz M; Berger MR; Theobald M; Galle PR; Moehler M; Schimanski CC
Int J Colorectal Dis; 2013 Mar; 28(3):385-98. PubMed ID: 22983756
[TBL] [Abstract][Full Text] [Related]
11. Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression.
Hsu C; Lin LI; Cheng YC; Feng ZR; Shao YY; Cheng AL; Ou DL
Clin Cancer Res; 2016 May; 22(10):2555-64. PubMed ID: 26603262
[TBL] [Abstract][Full Text] [Related]
12. Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells.
Liu CY; Tseng LM; Su JC; Chang KC; Chu PY; Tai WT; Shiau CW; Chen KF
Breast Cancer Res; 2013; 15(4):R63. PubMed ID: 23938089
[TBL] [Abstract][Full Text] [Related]
13. Strong enhancement by IGF1-R antagonists of hepatocellular carcinoma cell migration inhibition by Sorafenib and/or vitamin K1.
D'Alessandro R; Refolo MG; Lippolis C; Carella N; Messa C; Cavallini A; Carr BI
Cell Oncol (Dordr); 2018 Jun; 41(3):283-296. PubMed ID: 29470830
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines.
Rangwala F; Williams KP; Smith GR; Thomas Z; Allensworth JL; Lyerly HK; Diehl AM; Morse MA; Devi GR
BMC Cancer; 2012 Sep; 12():402. PubMed ID: 22963400
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of Raf-1 kinase inhibitory protein as a sorafenib resistance mechanism in hepatocellular carcinoma cell lines.
Kim JS; Choi GH; Jung Y; Kim KM; Jang SJ; Yu ES; Lee HC
J Cancer Res Clin Oncol; 2018 Aug; 144(8):1487-1501. PubMed ID: 29858683
[TBL] [Abstract][Full Text] [Related]
16. Ilexgenin A exerts anti-inflammation and anti-angiogenesis effects through inhibition of STAT3 and PI3K pathways and exhibits synergistic effects with Sorafenib on hepatoma growth.
Yang H; Wang J; Fan JH; Zhang YQ; Zhao JX; Dai XJ; Liu Q; Shen YJ; Liu C; Sun WD; Sun Y
Toxicol Appl Pharmacol; 2017 Jan; 315():90-101. PubMed ID: 27986624
[TBL] [Abstract][Full Text] [Related]
17. Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells.
Gu HR; Park SC; Choi SJ; Lee JC; Kim YC; Han CJ; Kim J; Yang KY; Kim YJ; Noh GY; No SH; Jeong JH
Clin Mol Hepatol; 2015 Mar; 21(1):49-59. PubMed ID: 25834802
[TBL] [Abstract][Full Text] [Related]
18. The synergistic antitumor effect of Huaier combined with 5-Florouracil in human cholangiocarcinoma cells.
Fu Z; Ma K; Dong B; Zhao C; Che C; Dong C; Zhang R; Wang H; Wang X; Liang R
BMC Complement Altern Med; 2019 Aug; 19(1):203. PubMed ID: 31391034
[TBL] [Abstract][Full Text] [Related]
19. Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib.
Yokoi K; Kobayashi A; Motoyama H; Kitazawa M; Shimizu A; Notake T; Yokoyama T; Matsumura T; Takeoka M; Miyagawa SI
Oncol Rep; 2018 Feb; 39(2):843-850. PubMed ID: 29251327
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib inhibits 5-fluorouracil-resistant gastric cancer cell growth.
Kim HM; Kim SA; Park SB; Cho JH; Song SY
Scand J Gastroenterol; 2017 May; 52(5):577-584. PubMed ID: 28110575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
